Choose from 1 of 104 CD73 antibodies, which have been validated in experiments with 662 publications and 721 images featured in our data gallery. Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications.

NT5E/CD73 (D7F9A) Rabbit mAb recognizes endogenous levels of total NT5E/CD73 protein. Human, Mouse, Rat. Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human NT5E/CD73 protein.

Anti-CD73 antibodies offer a great promise to counteract cancer onset and development in combination with other therapies (i.e. anti-PD-1mAbs), but what is the appropriate timing, dosing and administration sequence of these agents to be successful in combinatorial approaches?

Description: This AD2 monoclonal antibody reacts with human CD73, a 5'-ectonucleotidase that converts 5'-adenosine monophosphate to adenosine. CD73 is expressed on the surface of endothelial cells, as well as B and T cells, including some CD4+Foxp3+ regulatory T cells.

CD73, mainly by the production of adenosine, is critical in the suppression of an adequate anti-tumour immune response, but also in promoting cancer cell proliferation, tumour growth, angiogenesis, and metastasis.

CD73 (Ecto-5-prime-nucleotidase, 5-prime-ribonucleotide phosphohydrolase) catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. CD73 consists of a dimer of 2 identical 70 kDa subunits bound externally to the plasma membrane by a glycosyl phosphatidyl inositol linkage.

67789-1-Ig targets CD73 in WB, IHC, IF-P, ELISA applications and shows reactivity with human, mouse, rat samples. PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.